Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Sall

Otolaryngic Allergy Fayetteville, NY Medical Doctor

NPI 1710961198 CMS profile 259934

4000 Medical Center Dr., Ste 404, Fayetteville, NY 13066

Open in the dashboard

General payments

$20,478

83 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Sall of Fayetteville, NY is reported in the CMS Open Payments database as having received $20,478 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,406 15
2024 General $1,825 14
2023 General $421 11
2022 General $7,669 12
2021 General $7,585 15
2020 General $418 8
2019 General $155 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Sall
  • Otolaryngic Allergy median
  • Middle half of Otolaryngic Allergy
  • National median

In program year 2025, general payments to Edward Sall were reported at $2,406. Among 69 Otolaryngic Allergy profiles paid that year, the median was $420 and the middle half received between $149 and $981.

Show as a table
Year Edward Sall Otolaryngic Allergy median Middle half National median
2019 $155 $206 $52–$646 $163
2020 $418 $158 $40–$529 $114
2021 $7,585 $225 $68–$696 $132
2022 $7,669 $364 $108–$1,004 $149
2023 $421 $272 $123–$1,038 $160
2024 $1,825 $416 $129–$1,844 $164
2025 $2,406 $420 $149–$981 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Aerin Medical Inc. $19,678 45 payments
  2. Jazz Pharmaceuticals Inc. $153 7 payments
  3. Intersect ENT, Inc. $132 3 payments
  4. ALK-Abello, Inc $121 7 payments
  5. OptiNose US, Inc. $117 7 payments
  6. Regeneron Healthcare Solutions, Inc. $49 2 payments
  7. Kowa Pharmaceuticals America, Inc. $38 2 payments
  8. Stryker Corporation $38 2 payments
  9. Genzyme Corporation $35 2 payments
  10. Merck Sharp & Dohme Corporation $28 2 payments
  11. Other $88 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $8,107 4 payments
  2. Honoraria $6,600 1 payment
  3. Travel and Lodging $3,110 4 payments
  4. Food and Beverage $2,661 74 payments
Products named General payments · program years 2019–2025
  1. VIVAER STYLUS $19,407 42 payments
  2. RHINAER STYLUS $16,252 33 payments
  3. VivAer $246 2 payments
  4. RhinAer $246 2 payments
  5. Odactra $121 7 payments
  6. Xhance $117 7 payments
  7. Grastek $108 6 payments
  8. SUNOSI $97 4 payments
  9. Ragwitek $89 5 payments
  10. PROPEL $87 1 payment
  11. Other $368 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$72,489

Medicare's payments for the services billed

Medicare patients

543

Average age 72

Services billed

874

297 women, 246 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 50%
Diabetes 27%
Ischemic heart disease 26%
Depression 22%
Atrial fibrillation 17%
Osteoporosis 17%
Chronic kidney disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngic Allergy in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record